July 05, 2022
1 min watch
Save
VIDEO: Symptom management is ‘critical’ for treatment continuation in prostate cancer
Healio spoke with Daniel P. Petrylak, MD, about a presentation the American Urological Association meeting that focused on discontinuation rates of hormone therapy options among patients with advanced prostate cancer.
“In the overall scheme of things, symptom management and management of side effects is critical,” Petrylak, professor of medicine and urology at Yale University and co-leader of the Cancer Signaling Networks at Yale Cancer Center, said.
Reference
- Gangwish D, et al. Analysis of Discontinuation Rates and Causes of Early Discontinuation of Novel Oral Hormone Therapy in Men with Advanced Prostate Cancer. Presented at: American Urological Association meeting; May 13-16, 2022 (hybrid meeting).
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Petrylak reports serving as a consultant for Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Gilead Sciences, Infinity Pharmaceuticals, Ipsen, Merck & Company Inc, Monopteros, Pfizer, Sanofi Aventis Pharmaceuticals and Seagen; and receiving grant support from Ada Cap (Advanced Accelerator Applications), Arvinas, Astellas, AstraZeneca, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Company Limited, Endocyte, Ferring, Genentech, Gilead Sciences, Merck, Pfizer and Seagen.